Wellington Management Group LLP Makes New Investment in Acelyrin, Inc. (NASDAQ:SLRN)

Wellington Management Group LLP purchased a new stake in Acelyrin, Inc. (NASDAQ:SLRN - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 180,539 shares of the company's stock, valued at approximately $567,000. Wellington Management Group LLP owned 0.18% of Acelyrin as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Virtu Financial LLC acquired a new stake in Acelyrin during the 3rd quarter worth $50,000. HighTower Advisors LLC acquired a new stake in shares of Acelyrin during the third quarter worth about $50,000. Intech Investment Management LLC raised its position in shares of Acelyrin by 71.0% during the fourth quarter. Intech Investment Management LLC now owns 26,587 shares of the company's stock worth $83,000 after purchasing an additional 11,040 shares during the period. American Century Companies Inc. lifted its holdings in shares of Acelyrin by 146.0% during the 4th quarter. American Century Companies Inc. now owns 78,868 shares of the company's stock valued at $248,000 after purchasing an additional 46,802 shares in the last quarter. Finally, Barclays PLC grew its position in shares of Acelyrin by 208.8% in the 3rd quarter. Barclays PLC now owns 96,408 shares of the company's stock valued at $475,000 after purchasing an additional 65,188 shares during the period. Institutional investors and hedge funds own 87.31% of the company's stock.

Insider Buying and Selling at Acelyrin

In other Acelyrin news, CEO Mina Kim sold 17,986 shares of the company's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $2.74, for a total value of $49,281.64. Following the sale, the chief executive officer now owns 671,753 shares in the company, valued at $1,840,603.22. This represents a 2.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 13.60% of the company's stock.

Analysts Set New Price Targets

Several research firms recently commented on SLRN. Citigroup cut their price objective on shares of Acelyrin from $6.00 to $3.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 7th. HC Wainwright cut their price target on Acelyrin from $8.00 to $6.00 and set a "neutral" rating on the stock in a report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $9.60.

Acelyrin Stock Performance

SLRN remained flat at $2.20 during trading hours on Friday. 692,536 shares of the company traded hands, compared to its average volume of 1,217,903. The company has a market capitalization of $222.00 million, a PE ratio of -0.89 and a beta of 1.12. Acelyrin, Inc. has a fifty-two week low of $1.85 and a fifty-two week high of $7.25. The firm has a fifty day moving average price of $2.45 and a 200-day moving average price of $3.44.

Acelyrin (NASDAQ:SLRN - Get Free Report) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.79) EPS for the quarter, topping analysts' consensus estimates of ($0.86) by $0.07. As a group, sell-side analysts anticipate that Acelyrin, Inc. will post -2.53 EPS for the current fiscal year.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.